Optimization of pharmacokinetics through manipulation of physicochemical properties in a series of HCV inhibitors

ACS Medicinal Chemistry Letters

Volumn 2, Issue 10, 2011, Pages 715-719

  Lazerwith, Scott E ^a   Bahador, Gina ^a   Canales, Eda ^a   Cheng, Guofeng ^a   Chong, Lee ^a   Clarke, Michael O ^a   Doerffler, Edward ^a   Eisenberg, Eugene J ^a   Hayes, Jaclyn ^a   Lu, Bing ^a   Liu, Qi ^a   Matles, Mike ^a   Mertzman, Michael ^a   Mitchell, Michael L ^a   Morganelli, Philip ^a   Murray, Bernard P ^a   Robinson, Margaret ^a   Strickley, Robert G ^a   Tessler, Megan ^a   Tirunagari, Neeraj ^a   Wang, Jianhong ^a   Wang, Yujin ^a   Zhang, Jennifer R ^a   Zheng, Xubin ^a   Zhong, Weidong ^a   Watkins, William J ^a   more..

^a GILEAD SCIENCES   (United States)

Author keywords

3*HBD cLogP; HCV inhibitors; Pharmacokinetics; pyrido 3,2 d pyrimidine core

Indexed keywords

2 AMINO PYRIDO(3,2 D)PYRIMIDINE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG PENETRATION; HEPATITIS C VIRUS; LIPOPHILICITY; MEAN RESIDENCE TIME; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TISSUE DISTRIBUTION; VIRUS INHIBITION;

HEPATITIS C VIRUS; RATTUS;

EID: 80054740204     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200163b     Document Type: Article

References (12)

1. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 4-25
2. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates J. Med. Chem. 2002, 45, 2615-2623 (Pubitemid 34595232)
3. Leeson, P. D.; Davis, A. M. Time-Related Differences in the Physical Property Profiles of Oral Drugs J. Med. Chem. 2004, 47, 6338-6348 (Pubitemid 39587257)
4. Johnson, T. W.; Dress, K. R.; Edwards, M. Using the Golden Triangle to Optimize Clearance and Oral Absorption Bioorg. Med. Chem. Lett. 2009, 19, 5560-5564
5. Hou, T.; Wang, J.; Zhang, W.; Xu, X. ADME Evaluation in Drug Discovery. 7. Prediction of Oral Absorption by Correlation and Classification J. Chem. Inf. Model. 2007, 47, 208-218 (Pubitemid 46225576)
6. Martin, Y. C. A Bioavailability Score J. Med. Chem. 2005, 48, 3164-3170 (Pubitemid 40628036)
7. For a review, see Egan, W. J.; Lauri, G. Prediction of intestinal permeability Adv. Drug Delivery Rev. 2002, 54, 273-289 (Pubitemid 34260954)
8. Egan, W. J.; Merz, K. M., Jr. ; Baldwin, J. J. Prediction of Drug absorption Using Multivariate Statistics J. Med. Chem. 2000, 43, 3867-3877
9. Baldo, V.; Baldovin, T.; Trivello, R.; Floreani, A. Epidemiology of HCV Infection Curr. Pharm. Des. 2008, 14, 1646-1654 (Pubitemid 351998588)
10. Clarke, D. E. Rapid Calculation of Polar Molecular Surface Area and Its Application to the Prediction of Transport Phenomena. 1. Prediction of Intestinal Absorption J. Pharm. Sci. 1997, 88, 807-814 and references therein
11. Obach, R. S. Prediction of Human Volume of Distribution Using in vivo, in vitro, and in silico Approaches. In Annual Reports in Medicinal Chemistry; Macor, J. E., Ed.; Academic Press: London, United Kingdom, 2007; pp 469-488.
12. Raising lipophilicity significantly as a strategy for the improvement of bioavailability should be approached with caution, as compounds with high cLogP also tend towards other undesirable properties, such as poor solubility and poor selectivity. See Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nature Rev. Drug Discovery 2007, 6, 881-890 (Pubitemid 350042396)